To the Editor: Trivellin et al. (Dec. 18 issue)1 report a recurrent activating GPR101 mutation (p.E308D) in 11 of 248 tumor DNA samples from patients with isolated acromegaly. Of these patients, 3 carried a germline GPR101 mutation. Two of the 3 patients are being treated at our institution and were identified among 38 patients from our cohort. This might suggest a higher prevalence of germline...

Purpose. Excess growth hormone secretion in adults results in acromegaly, a condition in which multiple physical changes occur including bony and soft tissue overgrowth. Over time these changes can markedly alter a person's appearance. The aim of this study was to compare body image disturbance in patients with acromegaly to those with nonfunctioning pituitary adenomas (NFAs) and controls and a...

INTRODUCTION Acromegaly is a quite rare chronic disease caused by the increased secretion of growth hormone (GH) and subsequently insulin - like growth factor 1. Although cardiovascular diseases remains the most common cause of mortality among acromegalic patients, increased prevalence of malignant and benign neoplasms remains a matter of debate. The aim of this study is to evaluate the risk of...

BACKGROUND The treatment of acromegaly can be challenging. Despite a multimodality approach (surgery,radiation, dopamine agonists, somatostatin analogs), many patients do not achieve normalization of serum insulin-like growth factor I (IGF-I) concentrations. METHODS The author discusses the characteristics and indications of pegvisomant therapy for patients with acromegaly and compares the us...

OBJECTIVE It has been shown that genetic factors have a role in the development of acromegaly. We aimed to investigate the association between intercellular adhesion molecule (ICAM)-1 E469K polymorphism and some cardiovascular clinical parameters of acromegalic patients. PATIENTS AND METHODS We included 41 patients with acromegaly and 65 healthy subjects with similar age and sex to the study....

Introduction: There are several complications of the cardiovascular system caused by acromegaly, especially hypertension. Objectives: To evaluate hypertension characteristics in patients with cured/controlled acromegaly and with the active disease. Patients and methods: Cross-sectional study of the follow-up of forty-four patients with acromegaly submitted to clinical evaluation, laboratory tes...

Acromegaly is a chronic disease caused by overproduction of growth hormone, in most cases due to excessive secretion from a pituitary ad-enoma [1, 2]. The incidence of acromegaly is approximately 5 cases per million per year, and the prevalence is estimated to be about 60 cases per million [3]. Growth hormone (GH) induces the synthesis of insulin-like growth factor-1 (IGF-1), which leads to sev...

Hyperthyroidism is seen in 3.5-26% of acromegalic subjects, and can occur through TSH-dependent or independent mechanisms. Thyrotoxicosis as the first presenting illness in acromegaly is particularly uncommon, as described in this patient who had both acromegaly and a toxic thyroid adenoma.

Abstract Acromegaly is a rare, chronic disease that is, in more than 95% of cases, caused by growth hormone (GH)-secreting pituitary adenoma. Overproduction insulin-like factor-1 (IGF-1) due to GH hypersecretion leads various clinical features characterized somatic overgrowth, physical changes, multiple comorbidities, and increased mortality. The average age at diagnosis 40 50 years, with no se...

© Touch MEdical MEdia 2013 Abstract Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects ...